RxDoctor Payments Data

Timmy Nguyen, MD

Medical Oncology · Weston, FLNPI 1831243112

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (44.0%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. It is spread thinly across 44 manufacturers, the largest accounting for just 20.4%. Reporting peaked in 2024 at $15,745 and has fallen 50.6% since, to $7,777 in 2025.

$48,442in general payments, 2019–2025

Across 240 payments — averaging $201.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exelixis Inc.$10K
  • Immunogen, Inc.$7K
  • Ipsen Biopharmaceuticals, Inc$7K
  • Deciphera Pharmaceuticals Inc.$6K
  • AstraZeneca$5K
  • Avyxa Pharma, LLC$3K
  • plus $10K from 38 others
$383,517in research payments, 2019–2025

Across 27 payments — averaging $14,204 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Merck$268K
  • E.r. Squibb & Sons, L.L.C.$108K
  • Regeneron$8K

What the payments were for

  • Consulting fees$21,31344%
  • Speaking & faculty fees$15,55032%
  • Travel & lodging$4,96110%
  • Food & beverage$6,31813%
  • Education$3011%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$48,442 in reported general payments places this provider in the 85th percentile of 507 medical oncology providers in Florida.

See all medical oncology providers in Florida →

Medicare billing

Part B allowed, 2024
$433,702
Medicare patients
184
Services billed
14,307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide21$467,676
JakafiRuxolitinib Phosphate23$362,660
CabometyxCabozantinib S-Malate15$345,212
CreonLipase/Protease/Amylase13$32,373
Abiraterone Acetate17$15,196
EliquisApixaban15$15,151
XareltoRivaroxaban19$12,012
LinzessLinaclotide13$7,048
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen69$2,333
Oxycodone Hcl53$1,319
Morphine Sulfate ErMorphine Sulfate31$863
Omeprazole41$775
Ondansetron OdtOndansetron33$739
Dexamethasone35$732
LoperamideLoperamide Hcl28$682

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$14$467,67621 claims
Incyte CorporationJakafi$120$362,66023 claims
Exelixis Inc.Cabometyx$9,886$345,21215 claims
AbbVieCreon, Linzess$739$39,42126 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$11$15,19617 claims
PfizerEliquis$393$15,15115 claims
Johnson & JohnsonXarelto$1,341$12,01219 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 507 medical oncology providers in Florida.

Other medical oncology in Weston

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →